GBIM:OTCMKTS
GlobeImmune Inc
0,00010 $
0,00%
(0,00) 1 d.
29. sept., 15:48:52 GMT-4 · USD
search
Visi simboli
| Simbols | Cena | Izmaiņas | % izmaiņu |
|---|
insights_autoNotiek galveno ieskatu ģenerēšana par šādu tēmu: GBIM…
Tirgus kapitalizācija
580,00
Vid. apjoms
1,74 tūkst.
Apjoms
0,00
Augstākā 52 ned.
0,04 $
Zemākā 52 ned.
0,00 $
Apgrozībā esošās akcijas
5,75 milj.
Darbinieku skaits
22
Tirgus kapitalizācija
580,00
Vid. apjoms
1,74 tūkst.
Apjoms
0,00
Augstākā 52 ned.
0,04 $
Zemākā 52 ned.
0,00 $
Apgrozībā esošās akcijas
5,75 milj.
Darbinieku skaits
22
Ziņas un raksti
No tīmekļa avotiem un ziņu partneriem
Stock Titan
·
pirms 28 minūtēm
32 new hires get awards tied to 57,853 shares, but vesting depends on continued employment.
American Ag Network
·
pirms 22 minūtēm
NYSE Owner Challenges CME in Livestock Futures Market
Kursiv Media
·
pirms 22 minūtēm
Kazakhstani scooter-sharing operator JET eyes Nasdaq or LSE IPO after 2028
Yahoo Finance
·
pirms 34 minūtēm
1 Nasdaq 100 Stock on Our Watchlist and 2 That Underwhelm
Profils
GlobeImmune, Inc. is a clinical-stage public biopharmaceutical company headquartered in Louisville, Colorado, that develops therapeutic vaccines to treat cancer and infectious diseases. As of August 2014, the company had no marketed products. GlobeImmune’s therapeutic vaccines are developed on the company’s Tarmogen immunotherapy platform. Tarmogens are made from genetically modified yeast that express one or more disease-associated antigens. Tarmogens activate T cells to specifically target and eliminate diseased cells with the same target antigen.
The company has partnerships with Celgene and the National Cancer Institute for the development of cancer vaccines. Their collaboration with Gilead for the development of therapeutic vaccines for the treatment of hepatitis B was terminated in November 2016 after the product they were developing failed a clinical trial the year before.
With respect to financing in the absence of revenue, the company raised US$17,500,000 through a Series E Preferred Stock offering in January 2010.
As of August 2015, GlobeImmune had two therapeutic vaccines in clinical trials, GI-6207 and GI-6301, for the treatment of various cancers. Wikipedia
Par “GlobeImmune Inc”
Ģenerāldirektors-
Darbinieki22
Dibināšanas datums1995. gada 1. janv.
Galvenais birojsLouisville, Kolorādo, Amerikas Savienotās Valstis
Sektors-
Tīmekļa vietneglobeimmune.com